1. Home
  2. LCFY vs APVO Comparison

LCFY vs APVO Comparison

Compare LCFY & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Locafy Limited

LCFY

Locafy Limited

HOLD

Current Price

$4.22

Market Cap

8.4M

Sector

N/A

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$4.41

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCFY
APVO
Founded
2009
2016
Country
Australia
United States
Employees
18
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.4M
8.3M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
LCFY
APVO
Price
$4.22
$4.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
13.6K
41.3K
Earning Date
03-13-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.13
EPS
N/A
N/A
Revenue
N/A
$3,114,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$0.25
52 Week High
$13.98
$13.11

Technical Indicators

Market Signals
Indicator
LCFY
APVO
Relative Strength Index (RSI) 51.44 40.73
Support Level $4.07 $2.85
Resistance Level $4.80 $7.65
Average True Range (ATR) 0.24 0.32
MACD -0.07 0.01
Stochastic Oscillator 39.05 69.85

Price Performance

Historical Comparison
LCFY
APVO

About LCFY Locafy Limited

Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: